骨肉瘤与死亡原因:骨肉瘤协作研究组(COSS)1520例死亡患者报告
基于COSS数据库(1980年至2021年3月31日,4475例注册高级别中央型骨肉瘤患者)分析1520例死亡患者,中位死亡时间2.22年,84.6%死于骨肉瘤,9.6%死于其他原因,5.8%死因不明;化疗相关感染、第二恶性肿瘤和围手术期并发症是常见的潜在治疗相关死因。
要点
- 1520例死亡患者中84.6%死于骨肉瘤,其中370例未达完全缓解、488例首次复发、428例多次复发。
- 9.6%死于其他原因,5.8%死因不明;化疗相关感染40例、第二恶性肿瘤39例、围手术期并发症19例。
- 高剂量甲氨蝶呤(19例)、多柔比星(17例)和异环磷酰胺(15例)是常被归因的药物。
核心结论
- 骨肉瘤患者死亡的主要原因是骨肉瘤本身,多死于多次复发之一;但近10%的死亡由其他有记录的原因导致,其中部分可能通过全面分析获得的知识加以预防。
研究设计与样本
- 基于骨肉瘤协作研究组(COSS)数据库(1980年至2021年3月31日,4475例注册高级别中央型骨肉瘤患者)检索任何原因死亡,分析患者人口学和基线变量及死亡时疾病状态。
主要发现
- 共识别1520例死亡患者,诊断骨肉瘤时中位年龄16岁(范围2-78岁),男性908例(59.7%)、女性612例(40.3%)。
- 从诊断至死亡的中位时间为2.22年(范围0.08-32.02年)。
- 1286例(84.6%)死于骨肉瘤(370例未达完全缓解,488例首次复发,428例多次复发),146例(9.6%)死于其他原因,88例(5.8%)死因不明。
- 化疗相关感染(40例)、第二恶性肿瘤(39例)和围手术期并发症(19例)是最常见的潜在治疗相关死因,高剂量甲氨蝶呤(19例)、多柔比星(17例)和异环磷酰胺(15例)是常被归因的药物;死因不明患者的中位随访时间异常长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death. METHODS: The database of the Cooperative Osteosarcoma Study Group COSS (1980-03/31/2021; 4475 registered high-grade central osteosarcoma patients) was searched deaths from any cause. Affected patients were analyzed for demographic and baseline variables and disease-status at the time of demise. Deaths from causes other than osteosarcoma were analyzed in detail. RESULTS: A total of 1520 deceased patients were identified (median age (range) at osteosarcoma diagnosis 16 (2-78) years; 908 (59.7%) male, 612 (40.3%) female; primary tumor: extremities 1263 (83.1%), trunk 208 (13.7%), craniofacial 47 (3.1%) (site unknown 2); metastases at registration: absent 1.051 (69.1%), present 466 (30.7%) (3 no data). The median time from diagnosis to death was 2.22 (0.08-32.02) years. 1286 (84.6%) patients succumbed to osteosarcoma (370 without achieving complete remission, 488 first, 428 more than one recurrences), 146 (9.6%) to other, 88 (5.8%) to unknown causes. Chemotherapy-related infections (40), secondary malignancies (39), and perioperative complications (19) were among the most frequent potentially treatment-related causes, and high-dose methotrexate (19), doxorubicin (17), and ifosfamide (15) were the drugs most commonly held responsible. Patients with unknown causes of death had an unusually long median follow-up. CONCLUSION: The major cause of death of patients after osteosarcoma is this malignancy, mostly from one of its multiple relapses. However, almost 10% of fatalities are due to other documented causes. Some of these deaths may be preventable with the knowledge gained from comprehensive analyses such as this.
引用
- Bielack SS, Blattmann C, Borkhardt A, et al. Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). Eur J Cancer. 2022. PMID: 36191386. doi:10.1016/j.ejca.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。